Chile vs Congo, Democratic Republic of the: Antiretroviral therapy coverage
Chile
71.0%
in 2024
Congo, Democratic Republic of the
71.0%
in 2024
Chile rank
74th
Congo, Democratic Republic of the rank
74th
Antiretroviral therapy coverage over time
- Chile
- Congo, Democratic Republic of the
How they compare
Chile currently reports 71.0% against 71.0% in Congo, Democratic Republic of the, a difference of 0.0%.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was Chile ahead.
Chile ranks 74th and Congo, Democratic Republic of the ranks 74th of 143 countries.
Chile has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Chile | Congo, Democratic Republic of the | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 26.8% | 1.8% | 25.0% | Chile |
| 2010s | 57.2% | 22.0% | 35.2% | Chile |
| 2020s | 74.6% | 65.2% | 9.4% | Chile |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher antiretroviral therapy coverage, Chile or Congo, Democratic Republic of the?
- Chile, at 71.0% against 71.0% in Congo, Democratic Republic of the as of 2024.
- What is the difference in antiretroviral therapy coverage between Chile and Congo, Democratic Republic of the?
- 0.0%, with Chile ahead.
- How many years of comparable data are there for Chile and Congo, Democratic Republic of the?
- 25 years are reported by both, from 2000 to 2024.
- How do Chile and Congo, Democratic Republic of the rank globally for antiretroviral therapy coverage?
- Chile ranks 74th and Congo, Democratic Republic of the ranks 74th of 143 countries.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage (% of people living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.